LOQTORZI Growth Prospects
LOQTORZI is projected to grow to about $150 million to $200 million annually over the next three years, providing non-dilutive funding for the development pipeline and becoming an important revenue source as indications expand.
Positive Clinical Developments
CHS-114 showed a 40% reduction in target lesions in a late-line head and neck cancer patient, indicating potential to address PD-1 resistance. Additionally, a 17% complete response rate was observed in a liver cancer trial with casdozokitug.
Strategic Partnerships and Indication Expansion
Several agreements are in place to expand indications for toripalimab, including collaborations with INOVIO for HPV-positive head and neck cancer, and Junshi for small cell lung cancer.
Successful Restructuring and Cost Savings
The company expects $25 million in annualized savings from a reduced headcount post-UDENYCA divestiture, with more than half already realized.